WOLFGANG WINKELMAYER to Prolyl-Hydroxylase Inhibitors
This is a "connection" page, showing publications WOLFGANG WINKELMAYER has written about Prolyl-Hydroxylase Inhibitors.
Connection Strength
0.839
-
Novel anemia therapies in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2023 10; 104(4):655-680.
Score: 0.233
-
Vadadustat in Patients with Anemia and Non-Dialysis-Dependent CKD. N Engl J Med. 2021 04 29; 384(17):1589-1600.
Score: 0.202
-
Safety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis. N Engl J Med. 2021 04 29; 384(17):1601-1612.
Score: 0.202
-
Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney Int. 2021 06; 99(6):1280-1295.
Score: 0.201